Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective comparison of Azvudine vs Paxlovid in non-early high-risk COVID-19
ChiCTR2300071309Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of azvudine and Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Time to sustained clinical recovery. Planned start May 2023; status: not yet recruiting.
02
Drugs
azvudineNirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300071309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071309.